ClinicalTrials.gg
CompletedNCT05699239Updated Feb 28, 2025

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

A Phase 2 interventional study of TS-172 10mg bid and TS-172 30mg bid in Hyperphosphatemia Patients on Hemodialysis, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.

Enrollment
2nd of 36
326 · median 117
Started
2023
the only one that year
Phase 2
11 of 41
none open now
Registered
35th of 41
by date
Lead sponsor
7 of 41
Taisho Pharmaceutical Co., Ltd.

Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 2nd largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2023, is one of 11 in phase 2, and was the 35th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Hyperphosphatemia with a site in Japan, or all of them as a file.
02

Study summary

A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis

03

Conditions studied

  • Hyperphosphatemia Patients on Hemodialysis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to Visit 1 (Week -4)
  2. Patients aged ≥18 to \<80 years at the time of obtaining
  3. Patients with a serum phosphorus concentration of ≥ 3.5 mg/dL and ≤ 6.0 mg/dL at Visit 1 (Week -4)

Exclusion criteria

Exclusion Criteria:

  1. Patients with confirmed serum intact PTH concentration >500 pg/mL from Visit 1 (Week -4) to Visit 5 (Week 0)
  2. Patients with serum phosphorus concentration ≥ 10.0 mg/dL from Visit 2 (Week -3) to Visit 5 (Week 0)
  3. Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
326 participants (actual)

Study arms

  • Experimental
    10 mg bid

    Patients receive TS-172 10 mg bid.

    Drug: TS-172 10mg bid

  • Experimental
    30 mg bid

    Patients receive TS-172 30 mg bid.

    Drug: TS-172 30mg bid

  • Experimental
    60 mg bid

    Patients receive TS-172 60 mg bid.

    Drug: TS-172 60mg bid

  • Experimental
    20 mg tid

    Patients receive TS-172 20 mg tid.

    Drug: TS-172 20mg tid

  • Placebo comparator
    Placebo

    Patients receive placebo.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in serum concentration of phosphorus

    Time frame: Week 4

Secondary outcomes

  1. Achievement ratio of patients with the target serum concentration of phosphorus

    Time frame: Up to Week 4

  2. Concentration of corrected serum calcium

    Time frame: Up to Week 4

  3. Serum calcium times phosphorus product

    Time frame: Up to Week 4

07

Study locations

1 site
  • Taisho Pharmaceutical Co., Ltd selected site
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Dec 2023, 10 months.

Of 13 phase 2 interventional studies under Hyperphosphatemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 10. This study's 10 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Jan 26, 2023
StartActual
Feb 8, 2023
Primary completionActual
Dec 26, 2023
CompletionActual
Dec 26, 2023
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05699239
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Feb 8, 2023
Primary completion
Dec 26, 2023
Completion
Dec 26, 2023
Last update
Feb 28, 2025

Study contacts

Taisho Director
study director · Taisho Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TS-172

Start the discussion